ClinicalTrials.gg
RecruitingNCT07403474SMART-VAPUpdated Oct 13, 2026

Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Therapy in Critically Ill Patients With Ventilator-associated Pneumonia

A Phase 4 interventional study of strategy combining respiratory mPCR and algorithm-based therapy developed using local epidemiology in Ventilator Associated Pneumonia ( VAP), sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Pneumonia, Ventilator-Associated with a site in France — 20 open to participants now, 22 under way, 3 of them phase 3. Pneumonia, Ventilator-Associated · France.

Planned enrollment
28th of 47
124 · median 161
Started
2026
with 4 others
Phase 4
2 of 80
1 open now
Primary completion
2028-03
later than 17 of 21 live
Registered
77th of 80
by date
Lead sponsor
3 of 80
Centre Hospitalier Universitaire de Nīmes

Among the 80 studies in Pneumonia, Ventilator-Associated with a site in France, this one is the 28th largest by planned enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2026, is one of 2 in phase 4, reaches primary completion later than 17 of the 21 other live ones, and was the 77th registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

20 of the 80 studies in Pneumonia, Ventilator-Associated with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Pneumonia, Ventilator-Associated with a site in France, or all of them as a file.
02

Study summary

Assess the impact of a strategy combining respiratory mPCR and algorithm-based therapy developed using local epidemiology on the early optimization of initial antibiotic therapy for ventilator-associated pneumonia (VAP) (intervention), compared to a conventional strategy (control).

A bicentric, parallel-group, randomized controlled trial. The primary assessment criterion is the proportion of early optimized antibiotic therapy within 24 hours of respiratory sampling.

Read the detailed description

In both arms, for eligible patients with VAP, a deep respiratory sample collection is performed prior to inclusion. This collection is carried out either by mini bronchoalveolar lavage (BAL) via bronchoscopy or by blind mini BAL in alignment with the protocolized procedure. Initial antibiotic therapy is initiated after the deep sample has been taken according to the discretion of the attending clinician and in accordance with good practice recommendations. Both groups have their samples analyzed using conventional techniques. First, there is a direct examination, followed by culture and susceptibility testing, which is used as the gold standard technique for evaluating the primary endpoint.

In the intervention arm, in addition to conventional techniques, a broad-panel respiratory mPCR is performed before the 12th hour following achievement of the deep respiratory sample on the collected BAL. Once the mPCR results are received, the clinician adjusts the initial antibiotic therapy using algorithm-based therapy developed using local epidemiology in order to optimize treatment as early as possible.

In the control arm, the strategy is based on the clinician's choice in accordance with best practice recommendations without the combined use of respiratory mPCR and algorithm-based therapy. The deep respiratory sample is analyzed using conventional methods. Initial antibiotic treatment is therefore adapted by the clinician in charge of the patient according to departmental practices based on best practice recommendations, taking into account the results of the direct examination, culture, and susceptibility testing.

03

Conditions studied

  • Ventilator Associated Pneumonia ( VAP)

Keywords

  • mPCR
  • ventilator associated pneumonia
  • algorithm-based therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years) with VAP (mechanical ventilation and hospitalization ≥ 48 hours) and deep respiratory sample by mini BAL \< 12 hours. The diagnosis of pneumonia includes two clinical criteria among fever (≥38.3°C), purulent sputum or aspiration, hyperleukocytosis (>12,000 WBC/mm³) or leukopenia (\<4,000 WBC/mm³), hypoxemia, auscultatory signs in the affected area, and a newly-appeared parenchymal infiltrate
  • Patient receiving initial probabilistic antibiotic therapy for VAP suspicion
  • or emergency procedure
  • Patient affiliated with or beneficiary of a health insurance plan.

Non inclusion Criteria:

  • Pregnancy
  • Congenital immunodeficiency;
  • infection with the lymphocyte below 200/mm3 or unknown in the last year;
  • Acute hematologic ;
  • Neutropenia (\<1 leucocyte/mL or \< 0.5 neutrophil/mL);
  • drugs within the previous 30 days, including anti-cancer - Chemotherapy and anti-rejection drugs for organ/bone marrow transplant
  • ≥ 20 mg/d of prednisone equivalent for more than 14 days
  • Known allergy to beta-lactams
  • Moribund patient or death expected from underlying disease during the current admission;
  • Patient deprived of liberty or under legal protection measure;
  • Participation in another interventional trial.

Exclusion criteria

Exclusion criteria :

  • mPCR non available
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    combined use of mPCR and algorithm-based therapy

    strategy combining respiratory mPCR on a deep respiratory sample obtained by mini bronchoalveolar lavage and algorithm-based therapy developed using local epidemiology

    Procedure: strategy combining respiratory mPCR and algorithm-based therapy developed using local epidemiology

  • No intervention
    Conventional strategy for antibiotic therapy at discretion of ICU physicians

    The conventional strategy is based on the clinician's choice in accordance with best practice recommendations, without the combined use of respiratory mPCR and algorithm-based therapy.

Interventions

  • Procedurestrategy combining respiratory mPCR and algorithm-based therapy developed using local epidemiology

    strategy combining respiratory mPCR carried out either by mini bronchoalveolar lavage (BAL) via bronchoscopy or by blind mini BAL, and algorithm-based therapy developed using local epidemiology for the early optimization of initial antibiotic therapy

06

What researchers measure

Primary outcomes

  1. The effectiveness of a combined use a broad panel respiratory mPCR and an algorithm-based therapy developed using local epidemiology on the early optimization of initial antibiotic therapy for VAP, as compared to a conventional strategy

    Proportion of patients receiving optimized antibiotic therapy defined as effective antibiotic therapy and for which antibiotic de-escalation, when recommended, was performed early, within 24 hours after deep respiratory sampling.

    Time frame: Day 1

Secondary outcomes

  1. Duration of exposure to broad-spectrum antibiotic therapy.

    Average number of days of broad-spectrum antibiotic administration per patient at day 28

    Time frame: Day 28

  2. Compare expected and actual time frames for optimizing antibiotic therapy in the two arms.

    Time in hours between deep respiratory sampling and optimization of antibiotic therapy.

    Time frame: day 28

  3. Quantify early antibiotic de-escalation in the two groups under study

    Early and broad-spectrum antibiotic sparing according to the modified Antibiotic Spectrum Index (ASIm) de-escalation score (from No antibiotics (0) to very broad (≥8))

    Time frame: day 1 and day 7

  4. Rate of Clinical Cure at Day

    use test of cure at day 7

    Time frame: day 7

  5. Mechanical ventilation at day 28

    mechanical ventilation free-days at day 28

    Time frame: day 28

  6. lenght of stay in ICU at day 28

    ICU free-days at day 28

    Time frame: day 28

  7. Number of organ-failure free days (based on SOFA) at day 28

    Number of organ-failure free days (based on SOFA) at day 28

    Time frame: day 28

  8. Mortality at day 28

    Mortality at 28

    Time frame: day 28

  9. Sensitivity, specificity, and likelihood ratios of the broad panel mPCR Film Array for the diagnosis of pneumonia, taking the conventional microbiological tests as reference

    Sensitivity, specificity, and likelihood ratios of the broad panel mPCR Film Array for the diagnosis of pneumonia, taking the conventional microbiological tests as reference

    Time frame: day 28

  10. Incidence rates of infection or colonization with multidrug resistant bacteria and Clostridium difficile infections at day 28

    Incidence rates of infection or colonization with multidrug resistant bacteria and Clostridium difficile infections at day 28

    Time frame: day 28

  11. Cost of the total hospital admissions

    Total Hospitalization Cost per Participant at Day 28 (Including ICU Stay, Antimicrobial Therapy, Microbiological Diagnostic Workup, and Infection Relapse Costs)

    Time frame: day 28

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Jun 2026 → Mar 2026, primary completion Jul 2026 → Mar 2028 and completion Jul 2026 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 11, 2026
StartActual
Mar 27, 2026was Jun 2026
Primary completionEst.
Mar 27, 2028was Jul 2026
CompletionEst.
Apr 27, 2028was Jul 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
1 site added. CHU Nîmes is now Recruiting
Show site
  • CH ALES · Alès, France
Oct 13, 2026
Start date
Jun 1, 2026→Mar 27, 2026 (actual)
Oct 13, 2026
Primary completion
Jul 31, 2026→Mar 27, 2028
Oct 13, 2026
Study completion
Jul 31, 2026→Apr 27, 2028
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    1 site added. CHU Nîmes is now Recruiting
    Show site
    • CH ALES · Alès, France
    Start date Jun 1, 2026→Mar 27, 2026 (now actual)
    Primary completion Jul 31, 2026→Mar 27, 2028
    Study completion Jul 31, 2026→Apr 27, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07403474
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Mar 27, 2026
Primary completion
Mar 27, 2028 (estimated)
Completion
Apr 27, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Hugo MARTINIERE, PH
Contact
hugo.martiniere@chu-nimes.fr
+33 4 66 68 33 31

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion